EX-99.1 2 antx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 AN2 Therapeutics Reports Fourth Quarter and Full Year End 2025 Financial Results and Recent Business and Scientific Highlights Phase 2 study of oral epetraborole in polycythemia vera (PV) expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027 Advancing Phase 2 investigator-initiated trial of epetraborole in M.abscessus complex lung disease; Enrollment expected to begin in 1Q26 with topline results anticipated in late 2027 Chagas disease program progresses as Phase 1 first-in-human trial of oral AN2-502998 nears completion with initial clinical data expected in 1Q26; Initiation of Phase 2 proof-of-concept study in patients with chronic Chagas disease planned for 2026 pending results On track to advance two boron-based oncology compounds into development in 2026 March 2026 private placement extends runway into 2029 Menlo Park, CA - March 17, 2026 - AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results …
Open exhibit ↗Current Report · Items 2.02, 9.01 · 8-K
AN2 Therapeutics, Inc.
ANTXNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On March 17, 2026, AN2 Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter ended December 31, 2025. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.…
Company context
AN2 Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics derived from our boron chemistry platform. Our development pipeline spans hematologic diseases, infectious diseases, and oncology with three Phase 2 studies expected to be active in 2026, two preclinical candidates, as well as advanced research programs focused on targets in oncology, bone disorders, and infectious diseases. We are committed to delivering high-impact drugs to patients that address critical unmet needs and improve health outcomes.